Sasaki Masahiro, Kaneuchi Masanori, Fujimoto Seiichiro, Tanaka Yuichiro, Dahiya Rajvir
Department of Urology (112F), University of California-San Francisco and Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA.
Mol Cell Endocrinol. 2003 Apr 28;202(1-2):201-7. doi: 10.1016/s0303-7207(03)00084-4.
Multiple promoters and differential splicing of 5' upstream exons are often found in various nuclear receptor genes including steroid receptors. Three promoters control the expression of human estrogen receptor alpha (ERalpha) isoforms: ERalpha-A, ERalpha-B, and ERalpha-C, and two promoters control the expression of human progesterone receptor (PR) isoforms: PR-A and PR-B. The expression levels of these isoforms differ with respect to each other in certain target tissues. The role of these isoforms may differ in various types of cells and tissues. The ER and PR contain CpG islands in the 5' upstream regions. One possible mechanism for changing the transcriptional status is methylation of CpG-enriched regions in these isoforms. We have investigated the expression and methylation status of the three different ERalpha promoters and the two different PR gene promoters by using methylation specific PCR (MSP) and direct DNA sequencing in several endometrial and prostate cancer cell lines and tissues. The results of these experiments suggest that ERalpha-A, ERalpha-B, and PR-A were expressed and ERalpha-C and PR-B were inactivated in endometrial cancers. To the contrary, ERalpha-A and ERalpha-B were inactivated and ERalpha-C, PR-A and PR-B were expressed in all prostate cancer. Treatment with demethylating agent (5-aza-2'-deoxycytidine) restored these gene expressions, suggesting that inactivation of this gene is through methylation. Our MSP and direct DNA sequencing showed that ERalpha-A, ERalpha-B, and PR-A genes were unmethylated and ERalpha-C and PR-B were methylated in endometrial cancers although ERalpha-A and ERalpha-B were methylated and ERalpha-C, PRA and PRB were unmethylated in prostate cancers. These reports clearly demonstrate that selective hypermethylation can selectively silence multiple promoters of steroid receptors in carcinogenesis.
在包括类固醇受体在内的各种核受体基因中,经常发现多个启动子以及5'上游外显子的差异剪接。三个启动子控制着人类雌激素受体α(ERα)异构体的表达:ERα-A、ERα-B和ERα-C,两个启动子控制着人类孕激素受体(PR)异构体的表达:PR-A和PR-B。这些异构体的表达水平在某些靶组织中彼此不同。这些异构体的作用在各种类型的细胞和组织中可能有所不同。ER和PR在5'上游区域含有CpG岛。改变转录状态的一种可能机制是这些异构体中富含CpG区域的甲基化。我们通过甲基化特异性PCR(MSP)和直接DNA测序,在几种子宫内膜和前列腺癌细胞系及组织中研究了三种不同的ERα启动子和两种不同的PR基因启动子的表达及甲基化状态。这些实验结果表明,在子宫内膜癌中,ERα-A、ERα-B和PR-A表达,而ERα-C和PR-B失活。相反,在所有前列腺癌中,ERα-A和ERα-B失活,而ERα-C、PR-A和PR-B表达。用去甲基化剂(5-氮杂-2'-脱氧胞苷)处理可恢复这些基因的表达,表明该基因的失活是通过甲基化。我们的MSP和直接DNA测序显示,在子宫内膜癌中,ERα-A、ERα-B和PR-A基因未甲基化,而ERα-C和PR-B甲基化,尽管在前列腺癌中ERα-A和ERα-B甲基化,而ERα-C、PRA和PRB未甲基化。这些报告清楚地表明,在致癌过程中,选择性高甲基化可选择性地沉默类固醇受体的多个启动子。